Abstract: Variant Neublastin polypeptides having substitutions at selected amino acid residues are disclosed. Substitution at one or more selected amino acid residues decreases heparin binding and increases serum exposure of variant Neublastin polypeptides. Also disclosed are methods of using variant Neublastin polypeptides to treat disorders and activate the RET receptor in a mammal.

Abstract: Compositions and methods for treating Th2- and Th1-mediated disease are provided.

Abstract: An intelligence outdoor shading arrangement includes an outdoor shading system, an environmental sensor device and a functional controller. The outdoor shading system includes at least an outdoor shading device including a supporting frame, a power source, an awning frame suspendedly and movably supported by the supporting frame, and a shelter mounted to the awning frame to define a shading area under the shelter. The environmental sensor device is electrically linked to the power source and is installed to the outdoor shading system for detecting an environmental change of the shading system in responsive to the shading area thereof.

Abstract: The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.

Abstract: Various embodiments of the invention relate to a lighting control console for controlling a lighting system comprising wherein digital adjusting commands, which can be transferred to the lighting devices of the lighting system via data connections, are generated in the lighting control console, and wherein the lighting control console comprises at least one housing, in which the hardware components are arranged so as to be protected from external influences, and wherein the lighting control console comprises a plurality of operating elements, in particular pushbuttons, slide controls and/or rotary controls, which are arranged at the upper side of the housing and by means of which operating commands can be input, and wherein the lighting control console comprises at least one display device, at which a user interface can be displayed.

Abstract: Methods and systems for evaluating and/or monitoring chromatography column performance are provided. Embodiments apply multivariate analysis (MVA) methods to process data as well as transition analysis data to provide a comprehensive evaluation of chromatography column performance. In embodiments, transition analysis data generated over extended periods of time can be analyzed together with process data to evaluate column performance. Further, embodiments enable a compact and robust tool for combining and presenting performance evaluation results, which allows for time-efficient performance examination.

Abstract: The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.

Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.

Abstract: The present invention pertains to methods of increasing the efficiency of producing a bioproduct. In some embodiments, the method increases the quantity of a bioproduct produced, or decreases bioproduct production time, in a bioreactor cell culture producing the bioproduct, the method comprising, (a) intermittently or continuously analyzing the concentration of one or more nutrients in the bioreactor cell culture; and (b) adding to the bioreactor cell culture additional nutrient media when the concentration of the one or more nutrients is lower than a target value.

Abstract: A method for multi-selection gifting, including identifying a multi-selection gift, the multi-selection gift including a plurality of items of merchandise, and at least one selection rule governing selection of at least two of the items of merchandise, and interactively guiding a gift recipient in selecting at least one item of merchandise in accordance with the at least one selection rule, wherein each selection rule is a member of the group including allowing the gift recipient to select up to a specified total number of items of merchandise in the multi-selection gift, allowing the gift recipient to select items of merchandise in the multi-selection gift up to a specified total cost, and allowing the gift recipient to select items of merchandise in the multi-selection gift up to a specified total measure. A system and a computer-readable storage medium are also described and claimed.

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Abstract: Formulations of VLA-4 binding antibody are described.

Abstract: Methods of, and compositions for, treating central nervous system injury with an antagonist of an alpha4 subunit containing integrin are described.

Abstract: Method for the preparation of at least one compound with biological properties from blood, where said method is performed in sealed tubes at a pressure below atmospheric pressure, thereby reducing or preventing the bacterial contamination of the compound through handling. The method comprises the repetition, for as many times as is required, of the following steps: connecting a second container that is vacuum-sealed to an extraction device connected in turn to a first container that contains blood separated into fractions, waiting for a period of time until the required fraction(s) is/are transferred, and removing said second container, with it thus being possible to obtain several second containers with different compounds for different medical applications including biological therapies. The steps may be performed in a closed system, without removing the caps of the containers, or alternatively the first container may be opened prior to the introduction of the extraction device.

Abstract: Compounds of formula (I): that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Abstract: The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.

Abstract: The invention relates to the detection and quantitation of cyclodextrins and cyclodextrin derivatives in solutions comprising a protein. The invention further relates to methods of evaluating pharmaceutical preparations for the presence of residual cyclodextrins.

Abstract: This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.

Abstract: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.